|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Sales | |||||
| Cost of sales | |||||
| Gross profit | |||||
| Operating expenses: | |||||
| Selling, general and administrative | |||||
| Research and development | |||||
| Acquired in-process research and development expenses | |||||
| Litigation and settlement expense | |||||
| Total operating expenses | |||||
| Operating loss | |||||
| Other income (expense), net: | |||||
| Interest income and other income, net | |||||
| Interest expense | |||||
| Loss from equity method investments | |||||
| Loss on extinguishment of debt | |||||
| Change in fair value of common stock warrants | |||||
| Total other income (expense), net | |||||
| Loss before income taxes | |||||
| Income tax expense | |||||
| Net loss | |||||
| Other comprehensive income (loss): | |||||
| Unrealized gain (loss) on short-term investments | |||||
| Unrealized loss on cash flow hedges | |||||
| Foreign currency translation gains (losses) | |||||
| Comprehensive loss | |||||
| Net loss per share - basic (in dollars per share) | |||||
| Net loss per share - diluted (in dollars per share) | |||||
| Weighted average shares used to compute basic net loss per share (in shares) | |||||
| Weighted average shares used to compute diluted net loss per share (in shares) |
Loading...